We report on a patient with a long-standing history of recurrent oral aphthosis and pseudofolliculitis, diagnosed with Behçet's disease (BD), previously treated with high-dose prednisone, colchicine, cyclosporine, cyclophosphamide and methotrexate, all of which were partially effective. Treatment with the chimeric mouse-human anti-tumour necrosis factor (TNF)-α monoclonal antibody infliximab brought about the resolution of mucocutaneous lesions for a period of 6 years. After an oral and articular BD relapse, the anti-interleukin-6 agent tocilizumab was started in association with high-dose prednisone. Unexpectedly, the patient experienced a paradoxical mucocutaneous flare following tocilizumab administration, which worsened after the second infusion. Tocilizumab was then discontinued, and total recovery was achieved after the patient was started on the fully human anti-TNF-α monoclonal antibody golimumab in association with colchicine and methylprednisolone.

Cantarini, L., Lopalco, G., Vitale, A., Coladonato, L., Rigante, D., Lucherini, O.M., et al. (2015). Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. CLINICAL RHEUMATOLOGY, 34(6), 1141-1143 [10.1007/s10067-014-2589-z].

Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab

CANTARINI, LUCA;Vitale, Antonio;LUCHERINI, ORSO MARIA;
2015-01-01

Abstract

We report on a patient with a long-standing history of recurrent oral aphthosis and pseudofolliculitis, diagnosed with Behçet's disease (BD), previously treated with high-dose prednisone, colchicine, cyclosporine, cyclophosphamide and methotrexate, all of which were partially effective. Treatment with the chimeric mouse-human anti-tumour necrosis factor (TNF)-α monoclonal antibody infliximab brought about the resolution of mucocutaneous lesions for a period of 6 years. After an oral and articular BD relapse, the anti-interleukin-6 agent tocilizumab was started in association with high-dose prednisone. Unexpectedly, the patient experienced a paradoxical mucocutaneous flare following tocilizumab administration, which worsened after the second infusion. Tocilizumab was then discontinued, and total recovery was achieved after the patient was started on the fully human anti-TNF-α monoclonal antibody golimumab in association with colchicine and methylprednisolone.
2015
Cantarini, L., Lopalco, G., Vitale, A., Coladonato, L., Rigante, D., Lucherini, O.M., et al. (2015). Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. CLINICAL RHEUMATOLOGY, 34(6), 1141-1143 [10.1007/s10067-014-2589-z].
File in questo prodotto:
File Dimensione Formato  
Paradoxical-mucocutaneous-flare-Cantarini-2015.pdf

non disponibili

Descrizione: Articolo
Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 248.07 kB
Formato Adobe PDF
248.07 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/976492